Status | Study |
Recruiting |
Study Name: Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg Condition: Myelofibrosis Date: 2016-03-08 Interventions: Drug: Ruxolotinib Ruxolitinib |
Suspended |
Study Name: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor Condition: Primary Myelofibrosis Date: 2015-04-21 Interventions: Drug: Imetelstat 9.4 milligram/kilogram (mg/kg) |
Recruiting |
Study Name: Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis Condition: Myelofibrosis Date: 2015-02-06 Interventions: Drug: PIM447 pan-pim inhibitor |
Recruiting |
Study Name: Quantitative MRI for Myelofibrosis Condition: Myelofibrosis Date: 2013-10-25 Interventions: Procedure: T1 Weighted MRI (magnetic resonance imaging) En |
Active, not recruiting |
Study Name: Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis Condition: Myelofibrosis Date: 2013-03-14 Interventions: Drug: A: Fludarabine + Busulphan |
Active, not recruiting |
Study Name: Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis Condition: Myelofibrosis Date: 2012-12-24 Interventions: Drug: Peginterferon alfa-2a 50 mcg subcutaneous injection once per week |
Active, not recruiting |
Study Name: JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis Condition: Myelofibrosis Date: 2012-12-21 Interventions: Drug: Ruxolotinib Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT f |
Active, not recruiting |
Study Name: Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) Condition: Myelofibrosis Date: 2012-09-14 Interventions: Drug: Panobinostat PO TIW QOW |
Completed |
Study Name: Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients Condition: Myelofibrosis Date: 2011-04-21 Interventions: Drug: Ruxolitinib Ruxolitinib was supplied as SR and IR formulated tablets. |
Completed |
Study Name: Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis Condition: Myelofibrosis Date: 2010-06-22 Interventions: Drug: APLIDIN (plitidepsin) Aplidin® (plitidepsin) ly |